![]() | |
Clinical data | |
---|---|
Trade names | Ameile |
Other names | Almonertinib; HS-10296 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C30H35N7O2 |
Molar mass | 525.657 g·mol−1 |
3D model ( JSmol) | |
| |
|
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. [1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). [2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy. [3] [4]
{{
cite journal}}
: CS1 maint: DOI inactive as of April 2024 (
link)
![]() | |
Clinical data | |
---|---|
Trade names | Ameile |
Other names | Almonertinib; HS-10296 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C30H35N7O2 |
Molar mass | 525.657 g·mol−1 |
3D model ( JSmol) | |
| |
|
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. [1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). [2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy. [3] [4]
{{
cite journal}}
: CS1 maint: DOI inactive as of April 2024 (
link)